Printer Friendly

DEPRENYL USA INC. GRANTS MEDICIS RIGHT TO FIRST REFUSAL TO MARKET IN THE U.S.; POTENTIAL BREAKTHROUGH DRUG FOR SKIN CANCER, PSORIASIS, AND WARTS

 NEW YORK, May 11 /PRNewswire/ -- Medicis Pharmaceutical Corporation (NASDAQ: MDRXA) and Deprenyl USA Inc. (NASDAQ: DUSA) today announced they have agreed to certain amendments to the parties' Development Agreement dated Sept. 6, 1991 and have entered into a Right of First Refusal agreement for Medicis to market Aminolevulinic Acid Photodynamic Therapy (ALA PDT) in the United States for the treatment of dermatological conditions, including actinic keratoses, basal cell carcinomas, psoriasis and warts.
 Under the terms of the revised Development Agreement, monthly fees to Medicis will be paid for scientific, marketing and executive support and certain preapproved expenditures, but will not include development costs, which will be paid by Deprenyl USA Inc. directly to the firms performing those services. Completion of a marketing agreement is subject to certain terms and conditions. In the event the marketing agreement is terminated or if the Right of First Refusal is not implemented, Medicis may be entitled to receive a royalty on sales of ALA PDT in the United States for a period of five years for dermatological indications. Other terms of the agreements were not disclosed.
 "We are excited to be DUSA's U.S. dermatology partner with this potentially revolutionary product. Based upon human pilot studies in the treatment of superficial skin cancers and pre-cancers, ALA PDT offers patients an alternative to current therapies. In these preliminary studies, the treatment appeared to be safe and effective, with virtually no scarring. Given the fact that over 80 percent of skin cancers occur on the face, head, neck and hands, this relative lack of scarring could be an important advantage for ALA PDT," said Jonah Shacknai, Medicis' chairman and chief executive officer.
 Dr. Geoffrey Shulman, president and chief executive officer of Deprenyl USA, Inc. stated, "We are pleased to see the relationship between our two companies moving forward. With the ongoing depletion of the ozone layer and the rising incidences of both pre-cancerous and cancerous skin lesions, we believe ALA PDT will be an important drug in the treatment of skin cancer, as well as other dermatological conditions."
 ALA PDT represents a potential breakthrough for the treatment of certain skin conditions, such as actinic keratoses, basal cell carcinomas, psoriasis and warts. Applied topically and activated by a non-laser light source, ALA PDT selectively targets diseased cells and initiates a biochemical response which destroys the harmful cells, with minimal effects on normal cells. DUSA filed its first Investigational New Drug (IND) application with the FDA in December 1992. Phase I/IIA clinical trials began in February 1993 at the Department of Dermatology, University of California, Irvine, on actinic keratoses and psoriasis. Studies on basal cell carcinomas and other conditions are planned.
 The domestic markets for actinic keratoses, basal cell carcinoma and psoriasis are very large. Basal cell carcinoma is the most common form of cancer, affecting about 500,000 Americans annually, according to the Skin Cancer Foundation. Studies have also indicated the 55 percent of men and 37 percent of women in the U.S. between the ages of 65 and 74 years had actinic keratoses, resulting from extensive sun exposure during their lifetime. According to the National Center for Health Statistics, there were over 2.3 million chronic cases of psoriasis in 1991.
 Medicis Pharmaceutical Corporation currently markets 17 ethical and prescription products nationally which treat various dermatological conditions. The company also has several important products in late stage development.
 Deprenyl USA, Inc. is a development stage company established to bring prescription pharmaceutical products to worldwide markets initially in the United States and Canada, primarily in the field of Photodynamic therapy. For further information, contact, Dr. Geoffrey Shulman, DUSA's president and chief executive officer at 416-537-1070 or Jim Tolan, senior vice president, or Nicholas Biro, partner of O'Connor Biro & Associates, 708-498-2284.
 -0- 5/11/93
 /CONTACT: Kimberly Minarovich of Medicis, 212-599-2000/
 (MDRXA DU)


CO: Medicis Pharmaceutical Corporation; Deprenyl USA, Inc. ST: New York, New Jersey IN: MTC SU:

TS-LR -- NY078 -- 7184 05/11/93 15:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993
Words:661
Previous Article:CABOT OIL & GAS CORPORATION COMPLETES ACQUISITION
Next Article:BELL CANADA ISSUES DEBENTURES IN THE EUROPEAN MARKET
Topics:


Related Articles
NEW HOPE FOR VICTIMS OF SKIN AND INTERNAL CANCERS
DEPRENYL ACQUIRES CONTROL OF QUEBEC-BASED LIPOPHARM INC.
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
DEPRENYL USA'S EXPERIMENTAL DRUG HAS POTENTIAL AS 'TREATMENT OF CHOICE' FOR SKIN CANCERS, SAYS PRESIDENT; NAME CHANGED TO DUSA PHARMACEUTICALS
MEDICIS ANNOUNCES MARKETING AGREEMENT WITH WESTWOOD-SQUIBB
DEPRENYL RESEARCH LIMITED AND NOVOPHARM LIMITED ANNOUNCE STRATEGIC ALLIANCE
Inflazyme and SuperGen Consummate Licensing Agreement for Anti-Cancer Drugs

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters